Breaking news

Cyprus Study Uncovers Cellular Shield For Cancer & Genetic Disorders

A pioneering study from the University of Cyprus’s Laboratory of Cellular and Developmental Biology, in partnership with the University of Oxford, is set to redefine medical treatment paradigms. Published in Science Advances, the research uncovers a previously unknown mechanism by which cells fortify their nuclei against external mechanical forces—a discovery with profound implications for cancer treatment and rare genetic disorders.

Redefining Cellular Defense

Traditionally recognized for its role in DNA repair, the ATR protein has now been found to perform an additional, critical function. Researchers demonstrated that ATR relocates to the nuclear envelope, where it triggers the formation of a protective protein network known as nuclear actin. This reinforcement acts as an internal shield, safeguarding the nucleus from mechanical stress—particularly vital in tissues like the lungs, heart, and muscles that are constantly subjected to physical forces.

Read From Research to Reality: Cyprus’ Role In Creating Virtual Twins For Next-Gen Medicine

Transformative Medical Applications

The clinical potential of this breakthrough is immense. Diseases characterized by nuclear fragility—such as certain aggressive cancers, muscular dystrophies, and rare conditions like progeria—could be tackled more effectively by targeting this newly discovered pathway. By enhancing the resilience of the cell nucleus, future therapies might better prevent metastasis in cancer patients and improve outcomes in gene therapies aimed at correcting genetic disorders.

Lead author Dr. Maria Chatzifrangkeskou summed up the study’s significance:

“Our research highlights a crucial cellular mechanism that could serve as the foundation for new treatments in diseases where the nucleus is particularly vulnerable.”

A Catalyst for Future Innovations

This breakthrough not only expands our understanding of cellular biology but also positions Cyprus at the forefront of medical innovation. As scientists shift focus from traditional in vitro methods to in silico models—where large datasets power dynamic simulations of the human body—the implications extend beyond cancer therapy to a broader spectrum of diseases driven by nuclear instability.

Cypriot researchers are already making significant contributions to this field, bolstering the country’s reputation as a key player in Europe’s innovation ecosystem. By pushing the boundaries of how we model and treat complex biological systems, this study offers a glimpse into a future where personalized, predictive medicine is within reach.

This transformative discovery not only redefines how we perceive cellular protection but also opens new avenues for therapies that could change countless lives. With Cyprus leading the charge, the journey from research to revolutionary treatment is well underway.

Eurobank Buys Back €5.9 Million In Shares In One Week

Eurobank S.A. spent €5.88 million repurchasing more than 1.3 million of its own shares on Euronext Athens between August 17 and August 21, 2026.

The purchases are part of the bank’s ongoing share buyback programme, approved by shareholders at the annual general meeting on April 28 and launched following a public announcement on June 10.

More Than 1.3 Million Shares Repurchased

During the five-day trading period, Eurobank bought 1,312,998 shares for a total of €5,882,204.05, at an average price of about €4.48 per share.

The transactions were carried out on Euronext Athens through Eurobank Equities Single Member Investment Firm S.A.

Daily purchases were as follows:

  • August 17: 257,693 shares for €1.16 million, at an average of €4.4951 per share.
  • August 18: 271,616 shares for €1.22 million, averaging €4.4929.
  • August 19: 323,887 shares for €1.44 million, the largest daily purchase, at an average of €4.4336.
  • August 20: 237,344 shares for €1.06 million, averaging €4.4646.
  • August 21: 222,458 shares for €1.01 million, at an average of €4.5305.

Eurobank’s Share Holdings Increase

The buyback programme was formally established through a board resolution adopted on April 29, following shareholder approval and the relevant legal framework.

After the latest purchases, Eurobank holds a total of 22,500,675 of its own shares.

Aretilaw firm
Uol
eCredo
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter